96O Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial

C. Zhou, Shengxiang Ren, J. Chen, Xingxiang Xu, Ying Cheng, G. Chen, Yueyin Pan, Yong Fang, Q. Wang, Yunchao Huang, W. Yao, Ruoyu Wang, X. Li, W. Zhang, YANQIONG ZHANG, Sheng Hu, Renhua Guo, Zaibo Yang, L. Wang